White House weighs alternatives as Trump FDA nominee Heidi Overton lacks committee votes
President Trump's nominee to lead the FDA, Dr. Heidi Overton, is short of Republican support on the Senate health committee ahead of its Wednesday vote on her nomination.
The White House has begun looking at other candidates, including some who could serve in an acting capacity and skip Senate confirmation.
The nomination has foundered over Overton's testimony on the abortion drug mifepristone and her handling of Trump's pro-vaping policies.
Committee chairman Bill Cassidy says he is undecided and has questions about her support for Trump's August order cutting recommended childhood vaccines.
Republicans are racing to confirm nominees before Democrats take control of the Senate in January 2027.
Overton is a physician and Domestic Policy Council aide who played a significant role in the administration's health policy decisions.
On 15 November 2026, committee chairman Sen. Bill Cassidy said he still has questions about Overton, leaving the 18 November committee vote uncertain.
Sen. Susan Collins raised concerns about the FDA's authorization of flavored vapes.
Sen. Lisa Murkowski raised concerns about political pressure on scientific reviews and about mifepristone.
Cassidy said his choice is between backing a nominee about whom he holds reservations or voting no and leaving the FDA post unfilled as Democrats take control of Congress next year.
Overton has praised President Trump's August executive order reducing the number of recommended childhood vaccines as "historic".
At her September confirmation hearing, Overton called the combined measles, mumps and rubella vaccine "safe and effective", pushing back on Trump's characterization of the vaccine as "quite lethal".
Sen. Bill Cassidy said Heidi Overton's support for the executive order reducing childhood vaccines should be "almost disqualifying" for her nomination.
Dr. Heidi Overton, President Trump's pick to lead the FDA, is struggling to line up enough Republican support on the Senate Health, Education, Labor and Pensions Committee ahead of its Wednesday vote, and the nomination could be pulled.
The White House has begun looking at other candidates for FDA commissioner, including some who could serve in an acting capacity and forgo Senate confirmation during the three-week legislative window remaining.
Sen. Roger Marshall of Kansas, a doctor, is making a play for the FDA commissioner post, according to two sources.
Overton's nomination has run aground over her testimony on the abortion drug mifepristone and her execution of President Trump's pro-vaping policies while she served on the Domestic Policy Council.
Overton sidestepped questions at her confirmation hearing on how she would handle a safety study into mifepristone that the Trump administration has long promised.
Sen. Lisa Murkowski asked Overton at her confirmation hearing whether she would restrict mifepristone, and Murkowski and Sen. Susan Collins have not said whether they will vote to advance the nomination.
The vote to advance Overton and a handful of other health officials is scheduled for Wednesday morning.
In a Sunday television interview, Cassidy said, "Do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody's mind, but at least would be a permanent one and have the ability to establish some independence. And that's part of the thought process there. That weighs on one side, and of course other things weigh on the other."
Calley Means said in a television interview, "Heidi Overton was the biggest block to MAHA policies I encountered in the government."
Calley Means, a recently resigned MAHA leader and former adviser to Health and Human Services Secretary Robert F. Kennedy Jr., urged his followers to help block Overton's confirmation.
The anti-abortion group Susan B. Anthony urged the Senate to delay Overton's confirmation and wants the FDA to commit to banning mail orders of mifepristone.
